Current principles in the chemoprophylaxis of acute respiratory viral infections

Kharchenko E.P.; Shuldyakov A.A.; Liapina E.P.; Kuznetsov V.I.

doi:https://doi.org/

Kharchenko E.P.

Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia

ORCID: 0000-0001-6562-324X

Shuldyakov A.A.

Razumovsky Saratov State Medical University, Saratov, Russia

Liapina E.P.

Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo Minzdrava Rossii

Kuznetsov V.I.

Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo Minzdrava Rossii

Current principles in the chemoprophylaxis of acute respiratory viral infections

Authors:

Kharchenko E.P., Shuldyakov A.A., Liapina E.P., Kuznetsov V.I.

More about the authors

Journal: Therapeutic Archive. 2013;85(11): 27‑33

Read: 3399 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kharchenko EP, Shuldyakov AA, Liapina EP, Kuznetsov VI. Current principles in the chemoprophylaxis of acute respiratory viral infections. Therapeutic Archive. 2013;85(11):27‑33. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Aim. To evaluate the preventive efficacy of the Russian antiviral drug ingavirin (vitaglutam) in the epidemiological foci with the peak incidence of acute respiratory viral infections (ARVI). Subjects and methods. Four hundred men and women aged 18 to 65 years from the epidemic foci of ARVI who had been in close daily contact with the patients whose diagnosis was verified by laboratory tests were examined. Two hundred persons received prophylaxis with ingavirin (a 90-mg oral capsule once daily for 7 days) and 200 took placebo according to the same scheme. The efficiency index and coefficient were calculated and the relative risk of the disease was estimated to evaluate the efficiency of ARVI prevention. A pharmacoeconomic analysis was made. Results. There is evidence that the administration of 90-mg ingavirin capsules (OAO "Valenta Farm", Russia) caused a reduction in morbidity rates among those who had been in contact by 63% and in the risk of ARVI by 2.7 times. There was a reduction in the duration of fever by one day and a milder course of respiratory disease in the ingavirin-treated contact persons who developed ARVI. Conclusion. Ingavirin meets all requirements for current drugs for the nonspecific prevention of ARVI at the peak of its incidence. It has a pronounced protective effect and broad-spectrum activity, low toxicity and high safety, which allows it to be recommended for the emergency intrafocal prevention at the peak of the incidence of influenza and ARVI in adults.

Keywords:

chemoprophylaxis of respiratory diseases

emergency prophylaxis

Ingavirin

Authors:

Kharchenko E.P.

Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia

ORCID: 0000-0001-6562-324X

Shuldyakov A.A.

Razumovsky Saratov State Medical University, Saratov, Russia

Liapina E.P.

Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo Minzdrava Rossii

Kuznetsov V.I.

Saratovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. V.I. Razumovskogo Minzdrava Rossii

Close metadata

References:

VOZ. Inform byul 2009; 211.
Dawood F.S., Iuliano A.D., Reed C. et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12: 687-695.
Sinopal'nikov A.I. Prostuda. V kn.: Vnebol'nichnye infektsii dykhatel'nykh putei. M: Prem'er MT, Nash Gorod 2007: 131-144.
Gwalthey J.M. Jr. The common gold. In: Mandell G.L., Bennet J.F., Dolin R. (eds). Principles and practice of infectious diseases, 5th edn. Philadelphia: Churchill Livingstone 2000: 651-665.
Allander T., TaaniM.T., Bjerkner A. et al. Cloning of human parvovirus bu molecular screening of respiratory tract samplex. Proc Natl Acad Sci USA 2005; 102: 12891-12896.
Van den Hoogen B.G., de Long J.C., Groen J. et al. A newly discovered human pnemovirus isolated from young childer with respiratory tract disease. Nature Med 2001; 7: 719-724.
Hamelin M.E., Abed Y., Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin Infect Dis 2004; 38: 983-390.
CDC. Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 states, 2009. MMWR 2009; 58: 1341-1344.
Jain S., Kamimoto L., Bramley A.M. et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-1944.
Louie J.K., Acosta M., Winter K. et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896-1902.
Morgan O.W., Bramley A., Fowlkes A. et al. Morbid obesityas a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS ONE 2010; 5: e9694.
Thompson W.W., Shay D.K., Weintraub E. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-186.
Thompson W.W., Shay D.K., Weintraub E. et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-1340.
CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59: 8.
Osterholm M.T., Kelley N.S., Sommer A. et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 36-44.
Bautista E., Chotpitayasunondh T., Gao Z. et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-1719.
CDC. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-10 season. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at http://www.cdc.gov/H1N1flu/recommendations.htm.
Harper S.A., Bradley J.S., Englund J.A. et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1003-1032.
Ushkalova A.V. Protivovirusnye sredstva dlya profilaktiki grippa i drugikh respiratornykh infektsii. Trudnyi patsient 2006; 1: 10-13.
CDC. FluView: week ending May 20, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/flu/weekly. Accessed December 16, 2010.
CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR 2009; 58: 969-972.
Kaira A.N., Yushchenko G.V., Akhmadullina R.R., Cherkasova N.A. Nespetsificheskaya profilaktika grippa i ostrykh respiratornykh virusnykh infektsii preparatom Anaferon na territorii Moskovskoi oblasti. Infekts bol 2005; 3: 64-67.
Leneva I.A., Gus'kova T.A. Arbidol - effektivnyi preparat dlya lecheniya i profilaktiki grippa i ORVI: obzor rezul'tatov klinicheskikh issledovanii. Rus med zhurn 2008; 29: 1972-1976.
Lytkina I.N., Malyshev N.A. Profilaktika i lechenie grippa i ostrykh respiratornykh virusnykh infektsii sredi epidemiologicheski znachimykh grupp naseleniya. Lech vrach 2010; 10: 66-69.
Zarubaev V.V., Slita A.V., Sirotkin A.K. i dr. Eksperimental'noe izuchenie protivovirusnoi aktivnosti Ingavirina v otnoshenii adenovirusa cheloveka. Antibiotiki i khimioter 2010; 55: 9-10, 19-24.
Zarubaev V.V., Krivitskaya V.Z., Nebol'sin V.E. i dr. Eksperimental'noe izuchenie protivovirusnoi aktivnosti Ingavirina v otnoshenii virusa paragrippa cheloveka. Antibiotiki i khimioter 2010; 7-8: 13-16.
Loginova S.Ya., Borisevich S.V., Lykov M.V. i dr. Izuchenie aktivnosti Ingavirina in vitro v otnoshenii "meksikanskogo" pandemicheskogo podtipa H1N1 virusa grippa A, shtammy ?/California/04/2009 i A/Salifornia/07/2009. Antibiotiki i khimioter 2009; 3-4: 15-17.
Loginova S.Ya., Borisevich S.V., Maksimov V.A. i dr. Izuchenie lechebnoi effektivnosti novogo otechestvennogo preparata Ingavirin v otnoshenii vozbuditelya grippa A (N3N2). Antibiotiki i khimioter 2008; 7-8: 27-30.
Loginova S.Ya., Borisevich S.V., Maksimov V.A. i dr. Izuchenie effektivnosti Ingavirina in vitro v otnoshenii vozbuditelya adenovirusnoi infektsii. Antibiotiki i khimioter 2009; 7-8: 16-18.
Loginova S.Ya., Borisevich S.V., Shchukina V.N. i dr. Izuchenie protivovirusnoi aktivnosti Ingavirina v otnoshenii vozbuditelya "meksikanskogo" pandemicheskogo grippa A/H1N1/2009 in vitro i in vivo. Antibiotiki i khimioter 2010; 11-12: 17-21.
Loginova S.Ya., Borisevich S.V., Semenova I.V. i dr. Izuchenie protivovirusnoi effektivnosti Ingavirina v otnoshenii vozbuditelya grippa A(H3N2) v kul'ture kletok in vitro. Antibiotiki i khimioter 2009; 9-10: 23-26.
Kolobukhina L.V., Malyshev N.A., Merkulova L.N. i dr. Effektivnost' Ingavirina v lechenii grippa u vzroslykh. Ter arkh 2009; 3: 54-57.
Kolobukhina L.V., Merkulova L.N, Grigoryan S.S. i dr. Effektivnost' i bezopasnost' preparata Ingavirin v lechenii grippa i drugikh ORVI u vzroslykh. Spravochnik poliklinicheskogo vracha 2010; 9: 1-6.
Kolobukhina L.V., Merkulova L.N., Shchelkanov M.Yu. i dr. Pandemicheskii gripp v Rossii: otlichitel'nye osobennosti klinicheskogo techeniya i otsutstvie rannei etiotropnoi terapii kak faktor riska razvitiya tyazhelykh form zabolevaniya. Ter arkh 2011; 8: 12.
Loginova S.Ya., Borisevich S.V., Maksimov V.A. i dr. Izuchenie profilakticheskoi effektivnosti novogo otechestvennogo preparata Ingavirin v otnoshenii vozbuditelya grippa A (N3N2). Antibiotiki i khimioter 2008; 11-12: 19-21.
Belousov Yu.B., Karpov O.I., Leonova M.V. Kliniko-ekonomicheskaya otsenka sredstv, primenyaemykh dlya profilaktiki i lecheniya ORVI. Kachestvennaya klin prakt 2002; 5: 46-48.
Ershov F.I. Vozmozhna li ratsional'naya farmakoterapiya grippa i drugikh ORVI? Infektsiya i antimikrobnaya ter 2003; 6: 3-9.
Zupanets I.A., Nemchenko A.S. Sravnitel'nyi farmakoekonomicheskii analiz OTS-preparatov dlya simptomaticheskogo lecheniya ORVI i grippa. Provizor 2002; 23: 5-8.
Karpov O.I., Zaitsev A.A. Klinicheskaya farmakologiya osnovnykh sredstv dlya profilaktiki i lecheniya ORVI i grippa. SPb 2005; 24.
Shul'dyakova O.G. Kliniko-immunologicheskaya i profilakticheskaya effektivnost' tsikloferona v otnoshenii ostrykh respiratornykh virusnykh infektsii v organizovannykh kollektivakh: Avtoref. dis. ... kand. med. nauk. Saratov 2007; 23.
Kuznetsova I., Egorov A., Aschacher T. et al. Novel antiviral drug ingavirin restores the cellular antiviral response in influenza A virus infection and enhances viral clearance in ferrets. Mater. Evropeiskoi konf. po grippu. Germaniya, Myunster; 2-4 sentyabrya 2012 g. P. 124.